Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma.

MLA

Yoshino, Maki, et al. “Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma.” In Vivo (Athens, Greece), vol. 35, no. 5, Sept. 2021, pp. 2855–62. EBSCOhost, https://doi.org/10.21873/invivo.12573.

APA

Yoshino, M., Ishihara, H., Ishiyama, Y., Tachibana, H., Toki, D., Yamashita, K., Kobayashi, H., Fukuda, H., Yoshida, K., Takagi, T., Iizuka, J., Ishida, H., Kondo, T., & Tanabe, K. (2021). Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. In Vivo (Athens, Greece), 35(5), 2855–2862. https://doi.org/10.21873/invivo.12573

Chicago

Yoshino, Maki, Hiroki Ishihara, Yudai Ishiyama, Hidekazu Tachibana, Daisuke Toki, Kaori Yamashita, Hirohito Kobayashi, et al. 2021. “Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma.” In Vivo (Athens, Greece) 35 (5): 2855–62. doi:10.21873/invivo.12573.